**[List of drugs that may have potential CYP1A2 interactions]{.mark}**

CYP1A2 Substrates

+----------------+-----------------+----------------+-----------------+
| [Acenoco       | [Dul            | Estropipate    | Ropinirole      |
| umarol]{.mark} | oxetine]{.mark} |                |                 |
|                |                 | Flutamide      | Tacrine         |
| Aminophylline  | Estradiol       |                |                 |
|                |                 | Fluvoxamine    | Theophylline    |
| Betaxolol      | Estrogens,      |                |                 |
|                | conjugated      | Guanabenz      | Thiothixene     |
| Caffeine       |                 |                |                 |
|                | (synthetic)     | Mexiletine     | Tr              |
| Clomipramine   |                 |                | ifluoroperazine |
|                | Estrogens,      | Mirtazapine    |                 |
| Clozapine      | conjugated      |                |                 |
|                |                 | Pimozide       |                 |
| C              | (equine)        |                |                 |
| yclobenzaprine |                 | Propanolol     |                 |
|                | Estrogens,      |                |                 |
| Dacarbazine    | conjugated      | Riluzole       |                 |
|                |                 |                |                 |
| Doxepin        | (esterified)    |                |                 |
| []{.mark}      |                 |                |                 |
|                | Estrone         |                |                 |
+----------------+-----------------+----------------+-----------------+

**CYP 1A2** Inhibitors

+-----------------+-----------------+-----------------+-----------------+
| Albendazole     | Erythromycin    | Methimazole     | Propafenone     |
|                 |                 |                 |                 |
| Alosetron       | Estradiol       | Methoxsalen     | Propofol        |
|                 |                 |                 |                 |
| Amiodarone      | Estrogens,      | Mexiletine      | Propanolol      |
|                 | conjugated      |                 |                 |
| Amitriptyline   |                 | Miconazole      | Ranitidine      |
|                 | (synthetic)     |                 |                 |
| Amlodipine      |                 | Mirtazapine     | Rofecoxib       |
|                 | Estrogens,      |                 |                 |
| Anastrozole     | conjugated      | [Mocl           | Ropinirole      |
|                 |                 | obemide]{.mark} |                 |
| Atazanavir      | (equine)        |                 | Selegiline      |
|                 |                 | Modafinil       |                 |
| Bortezomib      | Ethinyl         |                 | Sertraline      |
|                 | estradiol       | Nalidixic acid  |                 |
| Bromocriptine   |                 |                 | Sildenafil      |
|                 | Fluconazole     | Nefazodone      |                 |
| Buprenorphine   |                 |                 | Sulconazole     |
|                 | Fluoxetine      | Nelfinavir      |                 |
| Caffeine        |                 |                 | Tacrine         |
|                 | Fluphenazine    | Nevirapine      |                 |
| Cimetidine      |                 |                 | Tenofovir       |
|                 | Flutamide       | Nifedipine      |                 |
| Ciprofloxacin   |                 |                 | Theophylline    |
|                 | Fluvastatin     | Nisoldipine     |                 |
| Citalopram      |                 |                 | Thiabendazole   |
|                 | Fluvoxamine     | Norfloxacin     |                 |
| Clarithromycin  |                 |                 | Thioridazine    |
|                 | Gemfibrozil     | Ofloxacin       |                 |
| Clotrimazole    |                 |                 | Ticlopidine     |
|                 | Ginseng (2)     | Olanzapine      |                 |
| Clozapine       |                 |                 | Tioconazole     |
|                 | Imipramine      | Omeprazole      |                 |
| Delavirdine     |                 |                 | Tocainide       |
|                 | Interferon-α2a  | Ondansetron     |                 |
| Dexmedetomidine |                 |                 | Tranylcypromine |
|                 | Interferon-α2b  | Orphenadrine    |                 |
| Diclofenac      |                 |                 | Verapamil       |
|                 | Interferon-γ1b  | Paroxetine      |                 |
| Disulfiram      |                 |                 | Zafirlukast     |
|                 | Isoniazid       | Pe              |                 |
| Drospirenone    |                 | ginterferon-α2a | Zileuton        |
|                 | Ketoconazole    |                 |                 |
| *Echinacea* (1) |                 | Pe              |                 |
|                 | Lidocaine       | ginterferon-α2b |                 |
| Enoxacin        |                 |                 |                 |
|                 | Lomefloxacin    | Pentoxifylline  |                 |
| Entacapone      |                 |                 |                 |
|                 | Losartan        | Perphenazine    |                 |
|                 |                 |                 |                 |
|                 | Mestranol       | Primaquine      |                 |
+-----------------+-----------------+-----------------+-----------------+

**CYP1A2** Inducers

+-----------------+-----------------+-----------------+-----------------+
| Am              | Phenobarbital   | Primidone       | Rifampin        |
| inoglutethimide |                 |                 |                 |
|                 |                 |                 |                 |
| Carbamazepine   |                 |                 |                 |
+-----------------+-----------------+-----------------+-----------------+

When drugs classified as 'substrates' are co-administered with *[(Study
Agent)]{.underline}*, there is the potential for higher concentrations
of the 'substrate'. When *[(Study Agent)]{.underline}* is
co-administered with compounds classified as 'inhibitors', increased
plasma concentrations of *[(Study Agent)]{.underline}* is the potential
outcome. The co-administration of 'inducers' would potentially lower
plasma *[(Study Agent)]{.underline}* concentrations.

[Note: Adapted from Cytochrome P450 Enzymes: Substrates, Inhibitors, and
Inducers. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL eds. Drug
Information Handbook 15^TH^ ed. Hudson, OH; LexiComp Inc. 2007:
1899-1912.]{.mark}

[Only major substrates and effective inducers are listed.]{.mark}

[Additional information for drug interactions with cytochrome P450
isoenzymes can be found at
<http://medicine.iupui.edu/flockhart/>]{.mark}.

\(1\) Gorski, *et al*. (2004). *Clin Pharmacol Ther*. 75:89-100.

\(2\) Saruwatari, *et al*. (2003). *J Pharm Pharmacol*. 55:1553-1559.

[Updated on May 1, 2007]{.mark}